Navigation Links
PAREXEL Consulting Enhances European Regulatory Affairs Capabilities With Appointment of Medical Products Agency Expert Dr. Anders Neil
Date:2/17/2009

BOSTON, Feb. 17 /PRNewswire-FirstCall/ -- PAREXEL Consulting, a business unit of PAREXEL International (Nasdaq: PRXL) and leading global consultancy serving the biopharmaceutical and medical device industries, has appointed Anders Neil, Ph.D., to the position of Principal Consultant in its European Product Development Practice. Dr. Neil, former Senior Expert, Pharmacology and Toxicology, at Sweden's Medical Products Agency (MPA), will advise clients on all aspects of clinical development and regulatory affairs. He joins the PAREXEL Consulting team of global experts, which includes former regulatory officials and biopharmaceutical industry professionals, focused on helping companies manage risk and maximize product and portfolio value at every milestone and during each phase of development.

With more than 20 years of experience, Mr. Neil's background includes pharmacology research, drug discovery, and drug development. Prior to working at the MPA, Dr. Neil's career included more than 10 years in the pharmaceutical industry, serving as Principal Scientist at Biovitrum AB as well as Group Manager, Pharmacology at Kabi-Pharmacia/Pharmacia & Upjohn.

"We expect clients will benefit greatly from the insight Dr. Neil has gained from helping to shape regulatory policies in Europe," said Peter Lassoff, Pharm D, Vice President, Europe, PAREXEL Consulting. "Dr. Neil's scientific advice and extensive regulatory and clinical experience will be invaluable in many areas, including in understanding new pediatric requirements as well as applying proactive safety strategies and risk management methodologies. He also brings a wealth of expertise in regard to product development in Sweden, which is the fourth largest biopharmaceutical market in Europe, to supplement our industry leading capabilities in Scandinavia."

"PAREXE
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. PAREXEL Reports Second Quarter Fiscal Year 2009 Financial Results
2. PAREXEL Announces Date of Second Quarter Fiscal Year 2009 Earnings Release and Conference Call
3. PAREXEL Reports Preliminary Second Quarter Results
4. PAREXEL International to Present at NASDAQ OMX 22nd Investor Program
5. PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results
6. PAREXEL International to Present at Robert W. Bairds 2008 Growth Stock Conference
7. PAREXEL International to Present at Bank of America 2008 Smid Cap Conference
8. Third-Party Audits: EHA Consulting Group Releases Comments on Food Safety Consultant Auditors' Qualifications and Competencies
9. Best Practice Database adds Research Highlighting the Value of Internal Consulting and Early-Stage Commercialization Groups in the Pharmaceutical Industry
10. New Study Provides Benchmarks for Best Practices for Valuing Internal Consulting Organizations
11. Brent McKenzie Joins ARMSRx Pharmacy Benefit Consulting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 24 (HealthDay News) -- New research suggests a ... people with insomnia. Every additional hour someone ... percent drop in the likelihood of moderate or ... the University of Pennsylvania. "We were ... sleep duration and suicide risk," study author, Linden ...
(Date:5/24/2013)... commonly used to treat glaucoma may cause droopy eyelids ... according to a new study. The drugs, known ... eye pressure, have already been shown to cause blurred ... said, suggesting that the new findings could lead to ... conservative when prescribing these drugs, the researchers added, particularly ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Area homeowners dreaming ... of new hot tubs to choose from at factory-direct pricing ... . The sales event takes place at Emerald Pool ... 2013. , Jacuzzi, the industry's leading hot tub brand, ... across the country. The event will feature popular hot tub ...
(Date:5/24/2013)... mutations central to the development of infantile myofibromatosis (IM)a ... and soft tissuemay provide new therapeutic targets, according to ... Sinai. The findings, published in the American Journal ... options for this debilitating disease, for which the only ... tumors. , IM is an inheritied disorder that develops ...
(Date:5/24/2013)... (HealthDay News) -- People with high levels of cadmium ... of liver disease than those with lower levels, a ... in urine is evidence of long-term exposure to the ... tobacco smoke, the Johns Hopkins researchers explained. They ... directly causes liver disease but instead suggest an association ...
Breaking Medicine News(10 mins):Health News:Sleep Duration Linked to Suicidal Thoughts in People With Insomnia 2Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Truckload of Jacuzzi® Hot Tubs Rolls into Bend, Oregon on May 24, 2013 for Sales Event 2Health News:Researchers identify first drug targets in childhood genetic tumor disorder 2Health News:High Cadmium Levels May Raise Risk for Dying From Liver Disease: Study 2
... Jan. 13 Genomma Lab Internacional,S.A.B. de C.V. (BMV: ... the main preliminary indicators obtained at the close of ... slightly lower results than the,original growth expectations. However, product ... line with original projections. , ...
... welcomes Los Angeles Mayor Antonio Villaraigosa, Cal State ... representatives and other dignitaries for the construction dedication ... 13 Today, Grifols SA (Grifols), a global ... Los Angeles Mayor Antonio Villaraigosa., Cal State LA ...
... WASHINGTON, Jan. 13 Speaker Nancy Pelosi released ... bipartisan legislation to expand the State Children,s Health ... Similar bipartisan legislation was vetoed twice by President ... bill, click here http://www.speaker.gov/newsroom/legislation?id=0270: "Today, the House ...
... The following was released today by the Office of the ... , On Wednesday, ... Health Insurance Program (SCHIP) Reauthorization bill. This bipartisan bill ... 11 million children -- preserving coverage for the 7 ...
... SRA International, Inc. (NYSE: SRX ), ... and solutions to government organizations and commercial clients, will ... release after close of market on Thursday, Feb. 5, ... call beginning at 5 p.m. EST.Interested parties may listen ...
... helped with pain, fatigue and depression, study shows ... may help people living with the chronic pain ... quality of life, new research shows. , The ... Saarbrucken in Germany, found that fibromyalgia patients had ...
Cached Medicine News:Health News:Grifols Celebrates Initial Construction of New IVIG Facility with Los Angeles Officials and Dignitaries 2Health News:H.R. 2, Bipartisan Children's Health Bill, Will Provide Coverage to 11 Million Children 2Health News:H.R. 2, Bipartisan Children's Health Bill, Will Provide Coverage to 11 Million Children 3Health News:H.R. 2, Bipartisan Children's Health Bill, Will Provide Coverage to 11 Million Children 4Health News:SRA Schedules Second Quarter Fiscal Year 2009 Earnings Release and Conference Call 2
(Date:5/23/2013)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... Chief Executive Officer of Neurocrine Biosciences, will be presenting at ... Conference in Boston.   The live presentation takes ... / 8:20 a.m. Pacific Time.  The presentation will be webcast ... http://www.neurocrine.com . If you are unable to ...
(Date:5/23/2013)... 23, 2013 Nephros, Inc. (OTC Bulletin Board: ... company that develops and sells high performance liquid purification ... offering.  In addition, the concurrent temporary reduction in exercise ... May 17, 2013. Nephros estimates that it ... rights offering.   A portion of the proceeds will be ...
(Date:5/23/2013)... May 23, 2013  A recently published clinical study ... Houston, Texas , demonstrates that 3D mammography (breast ... detection. The study, "Implementation of Breast ... was led by Stephen L. Rose ... the American Journal of Roentgenology (AJR). The ...
Breaking Medicine Technology:Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3
... POH, AIM: PSG, OTCQX: PPGNY) today announced that, ... Phase 1 transdermal,oxycodone clinical trial aimed at providing ... Phosphagenics has submitted all necessary documents for ... at CMAX - an independent clinical research,organization located ...
... First internal candidate to enter Phase 2 clinical ... PCOP ), an innovator in the discovery ... the initiation of a Phase 2a,clinical study of ... a dual-acting angiotensin and endothelin receptor antagonist,(DARA) that ...
Cached Medicine Technology:Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 4Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 5
... Aegis CheckPoint is an automated, ... logging and alert system for refrigerator, ... replace chart recorders, data loggers and ... installs on an existing PC and ...
... as three tests confirmed Sterillium Rub's extremely ... to FDA (Time Kill study and Tentative ... Products) and one European test - with ... relevant international efficacy specifications. Sterillium Rub with ...
Chlorhexidine Gluconate, exceptionally persistent and broad spectrum antimicrobial properties have led to its recognition as the most effective agent available for surgical scrubbing, hand washing, p...
Amino+Derm moisturizers and soaps are specifically engineered to aid in the prevention of skin irritations and to help maintain healthy, intact skin....
Medicine Products: